Precipio to Effect 1-for-15 Reverse Stock Split

Apr 26, 2019

|

NEW YORK (GenomeWeb) — Cancer diagnostics developer Precipio said today that it will implement a 1-for-15 reverse stock split in a bid to regain compliance with a Nasdaq listing requirements.

In a filing with the US Securities and Exchange Commission, New Haven, Connecticut-based firm said that it received notice late last month that it did not meet the exchange's $1 minimum bid price requirement and that its stock was facing delisting.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Scott Gottlieb Goes Back to His Old Job

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Where No CRISPR Has Gone Before

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Two Leave Emory

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

This Week in Science

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Featured White Papers

BlueBee Data Security & Compliance

Epigenomic Analysis of Sorted Retinal Ganglion Cells using ATAC-seq

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jun

13

Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Jun

18

Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.

Jun

19

Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jun

25

Featured Webinar

Menu